Show simple item record

dc.contributor.authorSperber, Nina R.
dc.contributor.authorDong, Olivia M.
dc.contributor.authorRoberts, Megan C.
dc.contributor.authorDexter, Paul
dc.contributor.authorElsey, Amanda R.
dc.contributor.authorGinsburg, Geoffrey S.
dc.contributor.authorHorowitz, Carol R.
dc.contributor.authorJohnson, Julie A.
dc.contributor.authorLevy, Kenneth D.
dc.contributor.authorOng, Henry
dc.contributor.authorPeterson, Josh F.
dc.contributor.authorPollin, Toni I.
dc.contributor.authorRakhra-Burris, Tejinder
dc.contributor.authorRamos, Michelle A.
dc.contributor.authorSkaar, Todd
dc.contributor.authorOrlando, Lori A.
dc.date.accessioned2021-08-03T12:38:19Z
dc.date.available2021-08-03T12:38:19Z
dc.date.issued2021-07-08
dc.identifier.urihttp://hdl.handle.net/10713/16280
dc.description.abstractThe complexity of genomic medicine can be streamlined by implementing some form of clinical decision support (CDS) to guide clinicians in how to use and interpret personalized data; however, it is not yet clear which strategies are best suited for this purpose. In this study, we used implementation science to identify common strategies for applying provider-based CDS interventions across six genomic medicine clinical research projects funded by an NIH consortium. Each project’s strategies were elicited via a structured survey derived from a typology of implementation strategies, the Expert Recommendations for Implementing Change (ERIC), and follow-up interviews guided by both implementation strategy reporting criteria and a planning framework, RE-AIM, to obtain more detail about implementation strategies and desired outcomes. We found that, on average, the three pharmacogenomics implementation projects used more strategies than the disease-focused projects. Overall, projects had four implementation strategies in common; however, operationalization of each differed in accordance with each study’s implementation outcomes. These four common strategies may be important for precision medicine program implementation, and pharmacogenomics may require more integration into clinical care. Understanding how and why these strategies were successfully employed could be useful for others implementing genomic or precision medicine programs in different contexts. © 2021 by the authors.en_US
dc.description.sponsorshipNational Institutes of Healthen_US
dc.description.urihttps://doi.org/10.3390/jpm11070647en_US
dc.language.isoenen_US
dc.publisherMDPI AGen_US
dc.relation.ispartofJournal of Personalized Medicineen_US
dc.subjectClinical decision supporten_US
dc.subjectGenomic medicineen_US
dc.subjectImplementation scienceen_US
dc.titleStrategies to integrate genomic medicine into clinical care: Evidence from the IGNITE networken_US
dc.typeArticleen_US
dc.identifier.doi10.3390/jpm11070647
dc.source.volume11
dc.source.issue7


This item appears in the following Collection(s)

Show simple item record